Source:http://linkedlifedata.com/resource/pubmed/id/11061576
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2000-11-3
|
| pubmed:abstractText |
To characterize steady-state indinavir pharmacokinetics in cerebrospinal fluid and plasma, 8 adults infected with human immunodeficiency virus underwent intensive cerebrospinal fluid sampling while receiving indinavir (800 mg every 8 hours) plus nucleoside reverse transcriptase inhibitors. Nine and 11 serial cerebrospinal fluid and plasma samples, respectively, were obtained from each subject. Free indinavir accounted for 94.3% of the drug in cerebrospinal fluid and 41.7% in plasma. Mean values of cerebrospinal fluid peak concentration, concentration at 8 hours, and area under the concentration-time profile calculated over the interval 0 to 8 hours [AUC(0-8)] for free indinavir were 294 nmol/L, 122 nmol/L, and 1616 nmol/L x h, respectively. The cerebrospinal fluid-to-plasma AUC(0-8) ratio for free indinavir was 14.7% +/- 2.6% and did not correlate with indexes of blood-brain barrier integrity or intrathecal immune activation. Indinavir achieves levels in cerebrospinal fluid that should contribute to control of human immunodeficiency virus type 1 replication in this compartment. The cerebrospinal fluid-to-plasma AUC(0-8) ratio suggests clearance mechanisms in addition to passive diffusion across the blood-cerebrospinal fluid barrier, perhaps by P-glycoprotein-mediated efflux.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0009-9236
|
| pubmed:author |
pubmed-author:BergqwistPP,
pubmed-author:ChamberlinSS,
pubmed-author:CloughL ALA,
pubmed-author:HaasD WDW,
pubmed-author:HarrisV LVL,
pubmed-author:HoaglandVV,
pubmed-author:JohnsonBB,
pubmed-author:JohnsonR HRH,
pubmed-author:KUW CWC,
pubmed-author:NicoteraJJ,
pubmed-author:RaffantiSS,
pubmed-author:SpearmanPP,
pubmed-author:StoneJJ,
pubmed-author:ZhongLL
|
| pubmed:issnType |
Print
|
| pubmed:volume |
68
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
367-74
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11061576-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:11061576-Administration, Oral,
pubmed-meshheading:11061576-Adult,
pubmed-meshheading:11061576-Area Under Curve,
pubmed-meshheading:11061576-Blood-Brain Barrier,
pubmed-meshheading:11061576-Drug Administration Schedule,
pubmed-meshheading:11061576-HIV Protease Inhibitors,
pubmed-meshheading:11061576-HIV-1,
pubmed-meshheading:11061576-Humans,
pubmed-meshheading:11061576-Indinavir,
pubmed-meshheading:11061576-RNA, Messenger,
pubmed-meshheading:11061576-RNA, Viral
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection.
|
| pubmed:affiliation |
Department of Medicine, Vanderbilt University School of Medicine, Nashville , Tenn 37212, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|